Skip to main content
The Oncologist logoLink to The Oncologist
. 2026 Nov 4;31(12):oyag435. doi: 10.1093/oncolo/oyag435

Immunotherapy and cancer: the CIPOMO viewpoint on challenges and opportunities

Giuseppe Aprile 1, Donatella Iacono 2,✉, Sandro Barni 3, Monica Giordano 4, Cinzia Ortega 5, Rosa Rita Silva 6, Paolo Tralongo 7, Luisa Fioretto 8; CIPOMODAY 2024 Scientific Committee
PMCID: PMC13759213  PMID: 42979999

The immunotherapy era and the CIPOMO perspective

In little more than a decade, immune checkpoint inhibitors (ICIs) have advanced from a promising option in advanced melanoma and non–small-cell lung cancer to a backbone of treatment across more than 20 solid-tumor indications.1–3 Unlike cytotoxic chemotherapy, ICIs can produce durable and occasionally complete responses, and a meaningful minority of patients with metastatic disease now become long-term survivors.4,5 This success has reshaped the daily work of oncology departments and, with it, the strategic priorities of those who lead them.

The Italian College of the Heads of Hospital Medical Oncology (CIPOMO, Collegio Italiano dei Primari Oncologi Medici Ospedalieri) brings together the directors of medical oncology units across Italy, from large academic centers to community hospitals. From this collective vantage point a consistent set of challenges—and corresponding opportunities—has come into focus. Here we set out what we regard as the defining strategic priorities of the immunotherapy era and the organizational and clinical responses they demand.

Toxicity is a system-level challenge, not only a clinical one

Although ICIs avoid much of the predictable toxicity of chemotherapy, they introduce immune-related adverse events (irAEs) that are mechanistically distinct, organ-agnostic, and at times life-threatening.6,7 Grade 3-4 events occur in a substantial fraction of patients, particularly with combination regimens, and rare but fatal complications such as myocarditis, encephalitis and pneumonitis demand immediate recognition.7,8 Managing these events is no longer the responsibility of the oncologist alone. It requires standing multidisciplinary networks linking cardiology, neurology, endocrinology, gastroenterology, dermatology and clinical immunology, supported by shared protocols and rapid-access pathways. International guidelines from ESMO and ASCO have done much to standardize care,9,10 but their local implementation—including the education of patients, caregivers and emergency staff who often encounter irAEs first—remains the practical challenge for departments. The decision to rechallenge after a significant irAE is a recurring dilemma that further underscores the need for structured, expert decision-making.11

A new and growing population: the long-term survivor

Perhaps the most profound consequence of immunotherapy is the emergence of a large cohort of long-term survivors of previously fatal metastatic disease.4 These patients raise questions for which oncology has limited precedent: how to govern survivorship care over years rather than months, how to manage chronic irAEs that persist long after treatment, and how to preserve quality of life during extended disease control. Chronic toxicities affecting endocrine, rheumatologic, dermatologic and neurologic systems are increasingly recognized, frequently requiring prolonged steroid exposure or permanent treatment discontinuation.12 Defining, monitoring and treating these persistent events is an urgent unmet need, and an opportunity to build dedicated survivorship pathways.13

Special populations and the limits of the evidence

The expansion of ICIs into the adjuvant and perioperative setting extends the promise of cure but shifts the risk–benefit balance: serious or chronic toxicity in a potentially cured patient carries a different weight than in advanced disease. Older adults, who constitute much of real-world practice, remain under-represented in pivotal trials, leaving questions about immunosenescence and tolerability inadequately answered.14 Patients with preexisting autoimmune disease face a genuine risk of exacerbation, yet clear guidance on which conditions contraindicate treatment is lacking.15,16 Each of these groups would benefit from deliberate inclusion in trials and from tailored, consensus-based recommendations.

When to stop treatment

The optimal duration of immunotherapy is among the most consequential open questions in the field. Stopping after a fixed period—often 2 years—in patients achieving a complete or major response has been proposed, but is not universally accepted, and the tradeoff between durable benefit, cumulative toxicity and cost remains unresolved.17 Reliable biomarkers to guide both initiation and cessation are still lacking; their development would transform patient selection and treatment de-escalation alike.18

Sustainability and the opportunity of innovation

Financial sustainability is a strategic concern at the system level. The cost of ICIs frequently exceeds departmental budgets, and not all agents offer comparable value.19 Whether individual agents are themselves interchangeable remains unsettled: anti-PD-1 and anti-PD-L1 antibodies differ in their molecular targets and pharmacological characteristics, and indirect comparisons suggest only modest differences in efficacy and toxicity, yet adequately powered head-to-head trials are almost entirely lacking.20 Where therapeutic equivalence within a class is supported by robust evidence, treating agents as interchangeable could increase competition in purchasing and strengthen price negotiation, with potentially substantial savings for health systems. Several innovations offer realistic relief. Subcutaneous formulations of established agents deliver comparable efficacy with administration in minutes rather than an hour, freeing chair time, enabling care models closer to the patient’s home, and—through future biosimilar competition—potentially reducing cost.21 Artificial intelligence holds promise for patient selection, response prediction and toxicity anticipation, although the complexity of real-world data and limited clinical validation temper near-term expectations. Such tools should be approached as aids to, not substitutes for, clinical judgment.

Table 1 outlines the key strategic challenges of the immunotherapy era and highlights the corresponding opportunities and potential strategies to address them.

Table 1.

Strategic challenges of the immunotherapy era and corresponding opportunities.

Strategic challenge Opportunity/response
Immune-related adverse events that are organ-agnostic and occasionally fatal Standing multidisciplinary irAE networks; shared protocols and rapid-access pathways; education of patients, caregivers and emergency staff
A growing population of long-term survivors of metastatic disease Dedicated survivorship pathways; systematic recognition and management of chronic irAEs
Under-represented groups: older adults, patients with autoimmune disease, the adjuvant setting Deliberate inclusion in trials; consensus guidance on contraindications and risk–benefit
Uncertain optimal treatment duration Biomarker-guided initiation and discontinuation; prospective de-escalation studies
Financial and organizational sustainability Subcutaneous formulations and biosimilars; AI-supported selection.

Conclusion

Immunotherapy has changed what oncology can offer, and in doing so has changed what oncology departments must become. The challenges we have outlined—system-level toxicity management, survivorship of metastatic disease, under-served populations, treatment duration, and financial sustainability—are not reasons to qualify past success but the agenda for consolidating it. Meeting them will require multidisciplinary networks, continuous professional development, deliberate inclusion of real-world populations in research, and the thoughtful adoption of innovations such as subcutaneous delivery, biomarker-guided selection and, in time, artificial intelligence. As the leaders of Italy’s hospital oncology units, CIPOMO regards these priorities as shared responsibilities of clinicians, institutions, researchers and policymakers alike. The opportunity before us is to ensure that the remarkable benefits of immunotherapy are delivered equitably, safely and sustainably to every patient who may gain from them.

Acknowledgments

The group member of the CIPOMODAY 2024 Scientific Committee are Giuseppe Aprile, Monica Giordano, Cinzia Ortega, Rosa Rita Silva, Giovanni Pietro Ianniello, Katia Cannita, Clementina Savastano, Antonio Iaria, Fabrizio Artioli, Alessandro Follador, Teresa Gamucci, Carlo Aschele, Andrea De Monte, Renato Bisonni, Roberta Buosi, Silvana Leo, Maria Giuseppina Sarobba, Stefano Vitello, Angela Stefania Ribecco, Orazio Caffo, Riccardo Rossetti, Teodoro Sava, Luigi Cavanna, Alberto Scanni, and Luisa Fioretto.

Contributor Information

Giuseppe Aprile, Department of Oncology, Ospedale Universitario Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, 33100, Italy.

Donatella Iacono, Department of Oncology, Ospedale Universitario Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, 33100, Italy.

Sandro Barni, Medical Oncology Unit, Ospedale di Treviglio, ASST Bergamo Ovest, Treviglio, Bergamo, 24047, Italy.

Monica Giordano, Medical Oncology Unit and Oncology Department, Ospedale Sant’Anna, ASST Lariana, San Fermo della Battaglia, Como, 22042, Italy.

Cinzia Ortega, Medical Oncology Unit, Ospedale “Michele e Pietro Ferrero”, ASL CN2 Alba-Bra, Verduno, Cuneo, 12060, Italy.

Rosa Rita Silva, Medical Oncology Unit, Ospedale di Fabriano, AST Ancona, Fabriano, Ancona, 60044, Italy.

Paolo Tralongo, Medical Oncology Unit, Oncology Care Network, Azienda Sanitaria Provinciale 8, Syracuse, 96100, Italy.

Luisa Fioretto, Medical Oncology Unit, Oncology Department, Azienda USL Toscana Centro, Florence, 50012, Italy.

CIPOMODAY 2024 Scientific Committee:

Giuseppe Aprile, Monica Giordano, Cinzia Ortega, Rosa Rita Silva, Giovanni Pietro Ianniello, Katia Cannita, Clementina Savastano, Antonio Iaria, Fabrizio Artioli, Alessandro Follador, Teresa Gamucci, Carlo Aschele, Andrea De Monte, Renato Bisonni, Roberta Buosi, Silvana Leo, Maria Giuseppina Sarobba, Stefano Vitello, Angela Stefania Ribecco, Orazio Caffo, Riccardo Rossetti, Teodoro Sava, Luigi Cavanna, Alberto Scanni, and Luisa Fioretto

Author contributions

Giuseppe Aprile (Conceptualization, Supervision, Validation, Writing—original draft, Writing—review & editing), Donatella Iacono (Data curation, Supervision, Validation, Writing—original draft, Writing—review & editing), Sandro Barni (Validation, Writing—review & editing), Monica Giordano (Validation, Writing—review & editing), Cinzia Ortega (Validation, Writing—review & editing), Rosa Rita Silva (Validation, Writing—review & editing), Paolo Tralongo (Validation, Writing—review & editing), and Luisa Fioretto (Validation, Writing—review & editing)

Funding

No funding.

Conflict of interest

Authors declare no competing interest.

References

  • 1. Postow MA, Callahan MK, Wolchok JD.  Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974-1982. 10.1200/JCO.2014.59.4358 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Reck M, Rodríguez-Abreu D, Robinson AG, et al.  Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823-1833. 10.1056/NEJMoa1606774 [DOI] [PubMed] [Google Scholar]
  • 3. Cancer Research Institute. 2025. Cancer Immunotherapy Insights + Impact Report. Accessed September 21, 2025. https://www.cancerresearch.org/blog/cancer-immunotherapy-insights-impact-2025-report
  • 4. Gauci M-L, Lanoy E, Champiat S, et al.  Long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin Cancer Res. 2019;25:946-956. 10.1158/1078-0432.CCR-18-0793 [DOI] [PubMed] [Google Scholar]
  • 5. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.  Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345-1356. 10.1056/NEJMoa1709684 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Postow MA, Sidlow R, Hellmann MD.  Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-168. 10.1056/NEJMra1703481 [DOI] [PubMed] [Google Scholar]
  • 7. Michot JM, Bigenwald C, Champiat S, et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-148. 10.1016/j.ejca.2015.11.016 [DOI] [PubMed] [Google Scholar]
  • 8. Wang DY, Salem J-E, Cohen JV, et al.  Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721-1728. 10.1001/jamaoncol.2018.3923 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Haanen JBAG, Carbonnel F, Robert C, et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142. 10.1093/annonc/mdx225 [DOI] [PubMed] [Google Scholar]
  • 10. Brahmer JR, Lacchetti C, Schneider BJ, et al.  Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714-1768. 10.1200/JCO.2017.77.6385 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Dolladille C, Ederhy S, Sassier M, et al.  Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6:865-871. 10.1001/jamaoncol.2020.0726 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Barron CC, Stefanova I, Cha Y, et al.  Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11:e006500. 10.1136/jitc-2022-006500 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Fletcher K, Johnson DB.  Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J Immunother Cancer. 2024;12:e008591. 10.1136/jitc-2023-008591 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Baladi A, Tafenzi HA, Zouiten O, et al.  Immunotherapy for elderly patients with advanced non-small cell lung cancer: challenges and perspectives. Int J Mol Sci. 2025;26:2120. 10.3390/ijms26052120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Antonuzzo A, Calabrò F, Quaglino P, et al.  Immunotherapy in underrepresented populations of patients with cancer: do we have enough evidence at present? A focus on patients with major viral infections and autoimmune disorders. Oncologist. 2020;25:e946-e954. 10.1634/theoncologist.2020-0035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Vogrig A, Muñiz-Castrillo S, Farina A, et al.  How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. J Neurol. 2022;269:1701-1714. 10.1007/s00415-021-10870-6 [DOI] [PubMed] [Google Scholar]
  • 17. Putzu C, Canova S, Paliogiannis P, et al.  Duration of immunotherapy in non-small cell lung cancer survivors: a lifelong commitment?  Cancers (Basel). 2023;15:689. 10.3390/cancers15030689 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Holder AM, Dedeilia A, Sierra-Davidson K, et al.  Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24:498-512. 10.1038/s41568-024-00705-7 [DOI] [PubMed] [Google Scholar]
  • 19. Verma V, Sprave T, Haque W, et al.  A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6:128. 10.1186/s40425-018-0442-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Duan J, Cui L, Zhao X, et al.  Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020;6:375-384. 10.1001/jamaoncol.2019.5367 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Burotto M, Zvirbule Z, Mochalova A, et al.  IMscin001 Part 2: a randomised phase III study of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2023;34:693-702. [DOI] [PubMed] [Google Scholar]

Articles from The Oncologist are provided here courtesy of Oxford University Press

RESOURCES